Imaging inflammation with 99Tcm-labelled chemotactic peptides

Pollak, Alfred; Goodbody, Anne E.; Ballinger, James R.; Duncan, Gordon S.; Tran, Lang; Dunn-Dufault, Robert; Meghji, Kumayl Abbas; Lau, Francis; Andrey, Tchorbanov; Boxen, Izzie; Sumner-Smith, Martin

doi:10.1097/00006231-199602000-00007

Cited by 30 publications

(22 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the rabbit infection model a transient decrease in WBC count of 35% was observed in all three groups during the first 30 min postinjection (183). A similar neutropenic response was also reported for the 99m Tc-labeled chemotactic peptides, [ 99m Tc]RP050 and [ 99m Tc]RP056 (184).…”

Section: Three Radiolabeling Approachessupporting

confidence: 79%

^99mTc Labeling of Highly Potent Small Peptides

1997

View full text Add to dashboard Cite

Section: Three Radiolabeling Approachessupporting

confidence: 79%

^99mTc Labeling of Highly Potent Small Peptides

1997

View full text Add to dashboard Cite

“…Several antagonists were developed to circumvent this undesirable biologic activity of the radiolabeled chemotactic peptide. However, these antagonists had lower uptake in the infectious focus, most likely due to reduced affinity for the receptor [43,44]. In summary, rapid imaging of infection and inflammation is feasible with radiolabeled chemotactic peptides, however, the undesired biologic side-effects of these peptides seem to impede further clinical development.…”

Section: Bacterial Chemotactic Peptidesmentioning

confidence: 99%

Radiopharmaceuticals for scintigraphic imaging of infection and inflammation

Boerman¹,

Dams²,

Oyen³

et al. 2001

Inflammation Research

View full text Add to dashboard Cite

Scintigraphic imaging of infection and inflammation is a powerful diagnostic tool in the management of patients with infectious or inflammatory diseases. Most infectious and inflammatory foci can be visualized accurately with radiolabeled autologous leukocytes. However, preparation of this radiopharmaceutical is laborious and requires the handling of potentially contaminated blood. Nowadays, a few radiopharmaceuticals are available that could replace radiolabeled leukocytes, such as: 67Ga-citrate, 99mTc-IgG and 99mTc-labeled antigranulocyte antibody preparations. Furthermore, various agents labeled with 99mTc are currently developed for this application: chemotactic peptides, cytokines and liposomes. Here, the characteristics and the diagnostic potential of established and experimental radiopharmaceuticals for infection and inflammation imaging are reviewed.

show abstract

“…In vivo labelling of WBCs with radiolabelled Mabs and their fragments and receptor-specific small Although there have been quite a number of studies with 99m Tc-GSH both as a tumor marker and in imaging inflammation [21,[196][197][198][199] its chemical structure was recently established, using the longer-lived 99 Tc isotope. In vivo labelling of WBCs with radiolabelled Mabs and their fragments and receptor-specific small Although there have been quite a number of studies with 99m Tc-GSH both as a tumor marker and in imaging inflammation [21,[196][197][198][199] its chemical structure was recently established, using the longer-lived 99 Tc isotope.…”

Section: Discussionmentioning

confidence: 99%

“…Fischman et al were the first to report the potential diagnostic use of In-111 labelled fMLP and they showed that a peptide dose as low as 10 ng/kg had a minimal effect on neutrophil blood level in monkeys [95]. Despite the disappointing early results that gave lower uptake and low target-to-background ratios due to lower receptor binding affinity [98], Pollak et al obtained increasing infection-to-background ratios, however, the absolute accumulation in the infectious site was still suboptimally low [99]. Subsequently, Babich et al described the synthesis of different analogs of fMLP, formyl-methionyl-leucyl-phenylalaninelysine conjugated to hydrazinonicotinamide and labelled with Tc-99m in the same rat model [96].…”

Section: Interleukin-1 Receptor Antagonists (Il-1ra)mentioning

confidence: 99%

Radiopharmaceuticals for the Visualization of Infectious and Inflammatory Lesions

Ercan¹,

Kostakoğlu²

2000

CPD

View full text Add to dashboard Cite

Many radiopharmaceuticals have been introduced for the scintigraphic demonstration of infectious and inflammatory lesions and some of them are currently in clinical use. They can be classified into two major categories according to their specificity. Specific radiopharmaceuticals include in vitro labeled leukocytes, radio-labelled monoclonal antibodies, and receptor specific small proteins and peptides. Nonspecific radiopharmaceuticals include radiolabelled nanocolloids, liposomes, macromolecules such as human immunoglobulin, dextran and human serum albumin, various small molecules and ions. In this review article radiopharmaceuticals in their respective groups are discussed as to the efficacy, and other parameters such as the physical characteristics of the radionuclides used, radiochemistry involved, availability, cost and biodistribution, emphasizing recent developments.

show abstract

Imaging inflammation with 99Tcm-labelled chemotactic peptides

Cited by 30 publications

References 0 publications

^99mTc Labeling of Highly Potent Small Peptides

^99mTc Labeling of Highly Potent Small Peptides

Radiopharmaceuticals for scintigraphic imaging of infection and inflammation

Radiopharmaceuticals for the Visualization of Infectious and Inflammatory Lesions

Contact Info

Product

Resources

About